A-EYE: A Mixed Quantitative and Qualitative Study to Develop and Evaluate the Application of Artificial Intelligence (AI) Methods Using Retinal Imaging for the Identification of Adverse Retinal Changes Associated With Cancer Therapies.

Overview

This is a data collection study involving the gathering of clinical data and OCT (optical coherence tomography) scans from 350 patients. The purpose of this study is to gather data to help develop an AI algorithm to detect eye abnormalities specifically those related to certain cancer treatments. At the end of the study interviews will be held with expert ophthalmologists to assess the acceptability of implementing AI into clinical practice.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2022

Detailed Description

Many cancer patients will access new treatments through clinical trials. These treatments have often never been tested in humans and therefore, are likely to have unknown side effects. Some of these side effects include changes to the eye, such as blindness. Ahead of patients taking part in these trials there is often little planning done to manage potential side effects on the eye. Additionally, accessing the expertise of eye specialists is not always available and often referral to a specialist is only given when eye symptoms have become advanced. These delays in identifying side effects on the eye also delays treatment and follow-up management. Providing patients access to this expertise would help in the detection and management of treatment side effects, however, due to demands on resources this access is not always readily available. The aim of this study is to create an artificial intelligence (AI) program that can detect changes to the eye related to disease, which, in the future, can be specifically used in cancer patient care. Additionally, developing an AI program to detect cancer related side effects to the eye will go a significant way in easing the burden on the health care system and improve side effects from new cancer treatments. This study will involve the collection of eye scans and medical data from participants at the Manchester Royal Eye Hospital. These will then be used to develop AI methods to detect changes in the eye related to those seen by patients on cancer treatment. The AI will then be compared with the assessments of eye specialists to assess if they give similar results.

Interventions

  • Other: No Intervention
    • This is an observational study

Clinical Trial Outcome Measures

Primary Measures

  • Measure of the diagnostic accuracy of the AI algorithm against gold standard clinical assessment associated with cancer treatment.
    • Time Frame: 12 months

Secondary Measures

  • Sensitivity of the AI in identifying clinically relevant lesions as defined by an ophthalmologist. Specificity of the AI in identifying clinically relevant lesions as defined by an ophthalmologist.
    • Time Frame: 12 months

Participating in This Clinical Trial

Inclusion Criteria

Patients are eligible for the study if all inclusion criteria are met: 1. Voluntary informed consent. 2. Aged at least 18 years. 3. Fully registered patient attending the Manchester Royal Eye Hospital 4. Patients are having an optical diagnostic imaging as part of their standard of care. Exclusion Criteria:

Patients are excluded from the study if any of the following criteria apply: 1. Patient who are deemed clinically unable to be scanned by healthcare professional.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Manchester
  • Collaborator
    • Institute of Cancer Research, United Kingdom
  • Provider of Information About this Clinical Study
    • Principal Investigator: Tariq Aslam, Professor Of Ophthalmology and Interface Technologies and Consultant Ophthalmologist – University of Manchester
  • Overall Contact(s)
    • Tariq Aslam, 0161 276 1234, tariq.aslam@manchester.ac.uk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.